|
Assay Development and High Throughput Screening Core |
5U54AG065181-04 |
|
NIA |
2022 |
|
Administrative and Data Management Core |
5U54AG065181-04 |
|
NIA |
2022 |
|
Open Drug Discovery Center for Alzheimers Disease |
5U54AG065187-04 |
|
NIA |
2022 |
|
Open Drug Discovery Center for Alzheimers Disease |
5U54AG065187-04 |
|
NIA |
2022 |
|
Open Drug Discovery Center for Alzheimers Disease |
5U54AG065187-04 |
|
NIA |
2022 |
|
Open Drug Discovery Center for Alzheimers Disease |
5U54AG065187-04 |
|
NIA |
2022 |
|
Open Drug Discovery Center for Alzheimers Disease |
5U54AG065187-04 |
|
NIA |
2022 |
|
Non-pharmacological Options in postoperative Hospital-based And Rehabilitation pain Management (NOHARM) pragmatic clinical trial |
5UH3AG067593-04 |
|
NIA |
2022 |
|
Molecular basis of activation of the orphan nuclear receptor Nurr1 |
6R01AG070719-03 |
|
NIA |
2022 |
|
Employment and Insurance Discrimination Based on Biomarkers for Alzheimers disease |
7K01AG057796-05 |
|
NIA |
2022 |